148 related articles for article (PubMed ID: 10980650)
1. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G
Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650
[No Abstract] [Full Text] [Related]
2. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
[No Abstract] [Full Text] [Related]
3. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Matsui W; Smith BD; Vala M; Beal N; Huff CA; Diehl LF; Jones RJ
Br J Haematol; 2005 Mar; 128(6):853-62. PubMed ID: 15755292
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
5. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
[TBL] [Abstract][Full Text] [Related]
6. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
Ofran Y; Avivi I; Gesundheit B; Or R; Rowe JM; Zuckerman T
Am J Hematol; 2007 Apr; 82(4):332-3. PubMed ID: 17080434
[No Abstract] [Full Text] [Related]
7. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
8. [Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome].
Shao X; Lu R; Guan X; Liu J; Zhao J; Shao Z; Zhan Z; Ma J
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):247-50. PubMed ID: 24666496
[No Abstract] [Full Text] [Related]
9. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
Park JW; Choi YJ; Jang MA; Baek SH; Lim JH; Passaniti T; Kwon TK
Biochem Biophys Res Commun; 2001 Aug; 286(4):726-34. PubMed ID: 11520058
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
13. [Progress of arsenic trioxide in treating myelodysplastic syndromes].
Xu S; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jan; 29(1):83-4. PubMed ID: 19338160
[No Abstract] [Full Text] [Related]
14. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
15. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
16. [Advances in the study on antineoplastic action of realgar].
Pan B; Xu L; Yang X
Zhong Yao Cai; 2004 Mar; 27(3):226-9. PubMed ID: 15346589
[No Abstract] [Full Text] [Related]
17. Morphological and biochemical changes induced by arsenic trioxide in neuroblastoma cell lines.
Ryu KH; Woo SY; Lee MY; Jung YJ; Yoo ES; Seoh JY; Kie JH; Shin HY; Ahn HS
Pediatr Hematol Oncol; 2005; 22(7):609-21. PubMed ID: 16166054
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
19. Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?
Stone RM
J Clin Oncol; 2006 Jun; 24(16):2414-6. PubMed ID: 16651644
[No Abstract] [Full Text] [Related]
20. Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer.
Kälkner KM; Ullén A; Wersäll P; Cohn-Cedermark G
Acta Oncol; 2007; 46(6):862-3. PubMed ID: 17653913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
